Effects of Topical or Intravitreal Application of Anti-Vascular Endothelial Growth Factor on Density of Intestinal Blood Vessels of Mice
Conclusions: The topical application or intravitreal injections of anti-VEGF agents do not cause a change in the VD of the intestinal vessels, which may be related to its safety.PMID:37109767 | PMC:PMC10143914 | DOI:10.3390/medicina59040809 (Source: Medicina (Kaunas))
Source: Medicina (Kaunas) - April 28, 2023 Category: Universities & Medical Training Authors: Atsushi Ichio Masahiko Sugimoto Yuhki Koike Yuji Toiyama Mineo Kondo Source Type: research
Effects of Topical or Intravitreal Application of Anti-Vascular Endothelial Growth Factor on Density of Intestinal Blood Vessels of Mice
Conclusions: The topical application or intravitreal injections of anti-VEGF agents do not cause a change in the VD of the intestinal vessels, which may be related to its safety.PMID:37109767 | PMC:PMC10143914 | DOI:10.3390/medicina59040809 (Source: Medicina (Kaunas))
Source: Medicina (Kaunas) - April 28, 2023 Category: Universities & Medical Training Authors: Atsushi Ichio Masahiko Sugimoto Yuhki Koike Yuji Toiyama Mineo Kondo Source Type: research
Effects of Topical or Intravitreal Application of Anti-Vascular Endothelial Growth Factor on Density of Intestinal Blood Vessels of Mice
Conclusions: The topical application or intravitreal injections of anti-VEGF agents do not cause a change in the VD of the intestinal vessels, which may be related to its safety.PMID:37109767 | PMC:PMC10143914 | DOI:10.3390/medicina59040809 (Source: Medicina (Kaunas))
Source: Medicina (Kaunas) - April 28, 2023 Category: Universities & Medical Training Authors: Atsushi Ichio Masahiko Sugimoto Yuhki Koike Yuji Toiyama Mineo Kondo Source Type: research
Effects of Topical or Intravitreal Application of Anti-Vascular Endothelial Growth Factor on Density of Intestinal Blood Vessels of Mice
Conclusions: The topical application or intravitreal injections of anti-VEGF agents do not cause a change in the VD of the intestinal vessels, which may be related to its safety.PMID:37109767 | PMC:PMC10143914 | DOI:10.3390/medicina59040809 (Source: Medicina (Kaunas))
Source: Medicina (Kaunas) - April 28, 2023 Category: Universities & Medical Training Authors: Atsushi Ichio Masahiko Sugimoto Yuhki Koike Yuji Toiyama Mineo Kondo Source Type: research
Effects of Topical or Intravitreal Application of Anti-Vascular Endothelial Growth Factor on Density of Intestinal Blood Vessels of Mice
Conclusions: The topical application or intravitreal injections of anti-VEGF agents do not cause a change in the VD of the intestinal vessels, which may be related to its safety.PMID:37109767 | PMC:PMC10143914 | DOI:10.3390/medicina59040809 (Source: Medicina (Kaunas))
Source: Medicina (Kaunas) - April 28, 2023 Category: Universities & Medical Training Authors: Atsushi Ichio Masahiko Sugimoto Yuhki Koike Yuji Toiyama Mineo Kondo Source Type: research
Effects of Topical or Intravitreal Application of Anti-Vascular Endothelial Growth Factor on Density of Intestinal Blood Vessels of Mice
Conclusions: The topical application or intravitreal injections of anti-VEGF agents do not cause a change in the VD of the intestinal vessels, which may be related to its safety.PMID:37109767 | PMC:PMC10143914 | DOI:10.3390/medicina59040809 (Source: Medicina (Kaunas))
Source: Medicina (Kaunas) - April 28, 2023 Category: Universities & Medical Training Authors: Atsushi Ichio Masahiko Sugimoto Yuhki Koike Yuji Toiyama Mineo Kondo Source Type: research
Effects of Topical or Intravitreal Application of Anti-Vascular Endothelial Growth Factor on Density of Intestinal Blood Vessels of Mice
Conclusions: The topical application or intravitreal injections of anti-VEGF agents do not cause a change in the VD of the intestinal vessels, which may be related to its safety.PMID:37109767 | PMC:PMC10143914 | DOI:10.3390/medicina59040809 (Source: Medicina (Kaunas))
Source: Medicina (Kaunas) - April 28, 2023 Category: Universities & Medical Training Authors: Atsushi Ichio Masahiko Sugimoto Yuhki Koike Yuji Toiyama Mineo Kondo Source Type: research
Effects of Topical or Intravitreal Application of Anti-Vascular Endothelial Growth Factor on Density of Intestinal Blood Vessels of Mice
Conclusions: The topical application or intravitreal injections of anti-VEGF agents do not cause a change in the VD of the intestinal vessels, which may be related to its safety.PMID:37109767 | PMC:PMC10143914 | DOI:10.3390/medicina59040809 (Source: Medicina (Kaunas))
Source: Medicina (Kaunas) - April 28, 2023 Category: Universities & Medical Training Authors: Atsushi Ichio Masahiko Sugimoto Yuhki Koike Yuji Toiyama Mineo Kondo Source Type: research
Effects of Topical or Intravitreal Application of Anti-Vascular Endothelial Growth Factor on Density of Intestinal Blood Vessels of Mice
Conclusions: The topical application or intravitreal injections of anti-VEGF agents do not cause a change in the VD of the intestinal vessels, which may be related to its safety.PMID:37109767 | PMC:PMC10143914 | DOI:10.3390/medicina59040809 (Source: Medicina (Kaunas))
Source: Medicina (Kaunas) - April 28, 2023 Category: Universities & Medical Training Authors: Atsushi Ichio Masahiko Sugimoto Yuhki Koike Yuji Toiyama Mineo Kondo Source Type: research
Effects of Topical or Intravitreal Application of Anti-Vascular Endothelial Growth Factor on Density of Intestinal Blood Vessels of Mice
Conclusions: The topical application or intravitreal injections of anti-VEGF agents do not cause a change in the VD of the intestinal vessels, which may be related to its safety.PMID:37109767 | PMC:PMC10143914 | DOI:10.3390/medicina59040809 (Source: Medicina (Kaunas))
Source: Medicina (Kaunas) - April 28, 2023 Category: Universities & Medical Training Authors: Atsushi Ichio Masahiko Sugimoto Yuhki Koike Yuji Toiyama Mineo Kondo Source Type: research
Effects of Topical or Intravitreal Application of Anti-Vascular Endothelial Growth Factor on Density of Intestinal Blood Vessels of Mice
Conclusions: The topical application or intravitreal injections of anti-VEGF agents do not cause a change in the VD of the intestinal vessels, which may be related to its safety.PMID:37109767 | PMC:PMC10143914 | DOI:10.3390/medicina59040809 (Source: Medicina (Kaunas))
Source: Medicina (Kaunas) - April 28, 2023 Category: Universities & Medical Training Authors: Atsushi Ichio Masahiko Sugimoto Yuhki Koike Yuji Toiyama Mineo Kondo Source Type: research
Refractive status and retinal morphology in children with a history of intravitreal ranibizumab for retinopathy of prematurity
Conclusion: Children with a history of type 1 ROP treated with ranibizumab did not show a myopic shift but did show abnormal retinal morphology and the poorest BCVA among all groups. We suggest that pediatric ophthalmologists should always pay attention to visual development in patients with ROP with a history of intravitreal ranibizumab.What is Known:• Anti-VEGF is efficiently and widely used in the treatment of type 1 retinopathy of prematurity (ROP), and different anti-VEGF agents are associated with different prevalence of myopia.• Patients with ROP who receive treatment such as laser therapy or cryotherapy have ab...
Source: European Journal of Pediatrics - April 25, 2023 Category: Pediatrics Source Type: research
Infographic: Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: the ANCHOR study
Eye, Published online: 24 April 2023; doi:10.1038/s41433-023-02397-zInfographic: Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: the ANCHOR study (Source: Eye)
Source: Eye - April 24, 2023 Category: Opthalmology Authors: Imran H. Yusuf Christin Henein Sobha Sivaprasad Source Type: research
Infographic: A randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia: the RADIANCE study
Eye, Published online: 21 April 2023; doi:10.1038/s41433-023-02392-4Infographic: A randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia: the RADIANCE study (Source: Eye)
Source: Eye - April 21, 2023 Category: Opthalmology Authors: Imran H. Yusuf Christin Henein Sobha Sivaprasad Source Type: research
Infographic: Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age-related macular degeneration: the BRAMD study
Eye, Published online: 21 April 2023; doi:10.1038/s41433-023-02398-yInfographic: Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age-related macular degeneration: the BRAMD study (Source: Eye)
Source: Eye - April 21, 2023 Category: Opthalmology Authors: Imran H. Yusuf Christin Henein Sobha Sivaprasad Source Type: research
